Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.4K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.4K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.1K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.1K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

591
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
591
Factors Affecting Renal Clearance: Drug Distribution and Drug Interactions01:09

Factors Affecting Renal Clearance: Drug Distribution and Drug Interactions

623
Renal clearance plays a pivotal role in drug elimination from the body and can be influenced by drug distribution and interactions. Understanding these factors is crucial in pharmacology as they impact the effectiveness and duration of drug therapy.
One important factor is the relationship between renal clearance and the apparent volume of distribution. Renal clearance tends to be inversely proportional to the apparent volume of distribution. Drugs with an extensive distribution volume or those...
623
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

566
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
566
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

608
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
608

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Combined large and small airway obstruction is associated with increased exacerbation frequency and poorer symptom control in persistent asthma.

The journal of allergy and clinical immunology. In practice·2026
Same author

Real-world effectiveness of tezepelumab on clinical remission and small airway dysfunction in severe asthma: a 52-week prospective study.

Expert opinion on biological therapy·2026
Same author

Pleiotropic effects of bempedoic acid on endothelial function and arterial stiffness: a preliminary study.

Journal of cardiovascular medicine (Hagerstown, Md.)·2026
Same author

Renal-diabetic overlap in pulmonary arterial hypertension.

Heart (British Cardiac Society)·2026
Same author

Small Airway Dysfunction May Mediate the Association Between Body Mass Index and Severe Asthma Exacerbations.

The European respiratory journal·2026
Same author

Allergen-specific immunotherapy at earlier stages of allergic respiratory diseases: a change is in the air!

Current opinion in allergy and clinical immunology·2026

Related Experiment Video

Updated: Mar 18, 2026

Multilevel Microdissection and Functional-Structural Profiling of Human Renal Arterial Branches
06:51

Multilevel Microdissection and Functional-Structural Profiling of Human Renal Arterial Branches

Published on: September 5, 2025

719

Cardiorenal Interactions.

Valentina Carubelli1, Carlo Lombardi1, Elio Gorga1

  • 1Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, P.zza Spedali Civili 1, Brescia 25123, Italy.

Heart Failure Clinics
|July 3, 2016
PubMed
Summary
This summary is machine-generated.

Heart failure patients often have kidney problems, increasing risks. This review covers cardiorenal syndrome, focusing on new biomarkers and therapies to protect kidney function in heart failure management.

Keywords:
Acute heart failureChronic kidney diseaseHeart failureRenal biomarkersRenal dysfunctionWorsening renal function

More Related Videos

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.7K
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

22.4K

Related Experiment Videos

Last Updated: Mar 18, 2026

Multilevel Microdissection and Functional-Structural Profiling of Human Renal Arterial Branches
06:51

Multilevel Microdissection and Functional-Structural Profiling of Human Renal Arterial Branches

Published on: September 5, 2025

719
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.7K
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

22.4K

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Renal dysfunction is a frequent and serious comorbidity in heart failure patients.
  • This condition significantly increases morbidity and mortality rates.
  • Effective management of cardiorenal syndrome is crucial for improving patient outcomes.

Purpose of the Study:

  • To review the epidemiology and pathophysiology of cardiorenal syndrome in heart failure.
  • To highlight novel biomarkers for early detection of renal damage.
  • To discuss improved pharmacological strategies for preserving renal function.

Main Methods:

  • Literature review of cardiorenal syndrome in heart failure.
  • Analysis of epidemiological data and pathophysiological mechanisms.
  • Evaluation of current and emerging therapeutic approaches.

Main Results:

  • Cardiorenal syndrome is complex, involving intricate interactions between the heart and kidneys.
  • Novel biomarkers show promise for earlier identification of renal impairment.
  • Emerging therapies offer potential for better renal function preservation.

Conclusions:

  • Early identification and management of renal dysfunction are vital in heart failure care.
  • Novel biomarkers and targeted therapies represent key advancements.
  • Addressing cardiorenal syndrome is essential for comprehensive heart failure treatment.